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Background
B-type natriuretic peptide (BNP) is a pleiotropic hormone
with important vasodilating, natriuretic, and antifibrotic
actions in the cardiovascular (CV) system. Recently it has
been shown that genetic variation affects BNP levels and
blood pressure [1,2]. We have demonstrated in a large US
general population cohort that the functional single
nucleotide polymorphism rs198389 in the promoter
region of the BNP gene is common and is associated with
higher BNP levels and certain clinical phenotypes [Cos-
tello-Boerrigter, L. C. et al.. in review]. he impact of con-
genitally elevated BNP levels on survival in the general
population or in subjects with cardiovascular disease is
unknown. The goal of this study was to determine the
impact of rs198389 on survival in a general US popula-
tion and in populations with specific CV diseases.
Methods
A random sample of the general population (≥ 45 years; n
= 1970) from Olmsted County, MN, was clinically charac-
terized (including echocardiogram), genotyped for
rs198389, and followed for mortality (median length of
follow-up: 5.6 years). Kaplan-Meier curves were generated
for genotypes using a dominant model (i.e. TT vs. TC+CC)
for all subjects combined and specific population sub-
groups.
Results
Genotype frequencies were in Hardy-Weinberg equilib-
rium (p = 0.98): TT 32.7%, TC 49.9%, and CC 17.3%. Sur-
vival in the total population was not different between
genotypes (p = 0.98). The same was true for subgroups
with hypertension (p = 0.20), coronary artery disease (p =
0.51), history of myocardial infarction (p = 0.36), left ven-
tricular ejection fraction ≤ 50% (p = 0.36) or ≤ 40% (p =
0.68). In contrast, C-alleles were associated with better
survival in patients classified as having moderate to severe
diastolic dysfunction (p = 0.02) and tended to have a bet-
ter survival in patients with type 2 diabetes mellitus (p =
0.065).
Conclusion
Congenitally elevated BNP levels due to rs198389 did not
affect survival in the general population and in several cat-
egories of CV disease but were associated with better out-
come in subjects with moderate to severe diastolic
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dysfunction. This also tended to be the case in subjects
with type 2 diabetes mellitus. Thus, the BNP genetic vari-
ant rs198389 does not affect survival in general but may
affect outcome in specific diseases. These findings require
confirmation in other populations.
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